Alvotech announced the initiation of a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi(R) and Simponi Aria(R) (golimumab). The study will assess the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi(R) in healthy adult subjects. In the twelve months up to October 2022, combined net revenues worldwide from sales of Simponi(R) and Simponi Aria(R) were over $2.2 billion, based on reported sales by the manufacturer of the reference product.

Alvotech's current portfolio of eight products and product candidates target treating autoimmune disease, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech's first marketed product, a biosimilar to Humira(R) (adalimumab), has been launched in Europe and Canada, and approved in 35 countries world-wide. Approval is pending in the United States.